Formulation and Characterization of Glimepiride Nanosuspension to Improve the Solubility and Release of Drug

Authors

  • Radheshyam Samanta Department of Pharmaceutics, Kalinga Institute of Pharmaceutical Sciences, Biruan, Balasore, 756060, Odisha, INDIA
  • Pravati Deo Department of Pharmachemistry, Kalinga Institute of Pharmaceutical Sciences, Biruan, Balasore, 756060, Odisha, INDIA
  • Ranjit Kumar Sutar Department of Pharmacology, Kalinga Institute of Pharmaceutical Sciences, Biruan, Balasore, 756060, Odisha, INDIA
  • Hrushikesh Behera Department of Pharmacology, Kalinga Institute of Pharmaceutical Sciences, Biruan, Balasore, 756060, Odisha, INDIA
  • Tamal Deb Goswami Department of Pharmaceutics, Kalinga Institute of Pharmaceutical Sciences, Biruan, Balasore, 756060, Odisha, INDIA
  • Ayush Panda Department of Pharmacy, Kalinga Institute of Pharmaceutical Sciences, Biruan, Balasore, 756060, Odisha, INDIA

DOI:

https://doi.org/10.55544/jrasb.5.3.16

Keywords:

Nanosuspension, Antisolvent, Polyethylene Glycol, Polyvinyl Pyrrolidone

Abstract

The present research work attempt to formulation and characterization of glimepiride nanosuspension made of polyethylene glycol 400 and polyvinyl pyrrolidone K30 with the help of antisolvent precipitation method was developed. These glimepiride containing nanosuspension were evaluated their particle size and size distribution, zeta potential, saturation solubility, drug entrapment efficiency and drug content uniformity. In addition, in vitro drug release was performed. After evaluation, different evaluated parameters like their zeta potential, saturated solubility, drug entrapment efficiency, drug content uniformity was showing valuable result to maintain the stability of nanosuspension. Also in vitro release of drug firstly high in phosphate buffer (pH- 7.8), after one hours the release rate maintain sustainly to all formulation specially GNS5 then other. This is because increase the concentration of polymers composition. So this research work, it was clearly stated that the formulation of glimepiride nanosuspension prepared by addition of suitable polymeric mixture, namely polyethylene glycol 400 and polyvinyl pyrrolidone K30 with others ingredients to improve the solubility and sustain release the drug for a prolong periods of time which is very useful to other insoluble drugs.

Downloads

Download data is not yet available.

References

[1] Chan, V. S. (2010). Nanomedicine: An unresolved regulatory issue. Regulatory Toxicology and Pharmacology, 46, 218–224.

[2] Shegokar, R., & Müller, R. H. (2010). Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives. International Journal of Pharmaceutics, 399, 129–139.

[3] Abdulbaqi, M. R., Taghi, H. S., & Jaafar, Z. M. (2021). Nanosuspension as an innovative nanotechnology trend drug delivery system: A review. Benefits, 2(10), 1–11.

[4] Jadhav, S. P., Singh, S. K., & Chawra, H. S. (2023). Review on nanosuspension as a novel method for solubility and bioavailability enhancement of poorly soluble drugs. Advances in Pharmacology and Pharmacy, 11(2), 117–130.

[5] Sharma, P., Bose, S., Moudgil, A., Arora, D., Sushila, S., Vyas, M., & Tomar, B. (2023). Nanosuspension as a promising drug delivery approach for the antidiabetic drug: An inclusive review on technology and future aspects. AIP Conference Proceedings, 2800.

[6] Ahamed, M. I., Akiladevi, D., & Karthick, G. (2022). A comprehensive review of a new nanosuspension for improving the oral bioavailability of poorly soluble drugs. Journal of Pharmaceutical Research International, 16–21.

[7] Tupe, A., & Mankar, S. D. (2023). Nanosuspension: A novel approach to improve the solubility, bioavailability and pharmacokinetics of poorly soluble drugs. Asian Journal of Pharmacy and Technology, 13(3), 194–200.

[8] Pınar, S. G., Oktay, A. N., Karaküçük, A. E., & Çelebi, N. (2023). Formulation strategies of nanosuspensions for various administration routes. Pharmaceutics, 15(5), 1520.

[9] Singh, S., & Bharati, D. (2024). Nanosuspensions: A novel drug delivery system. Scholars Academic Journal of Pharmacy, 5, 153–162.

[10] Tian, Y., Wang, S., Yu, Y., Sun, W., Fan, R., Shi, J., & Zheng, A. (2022). Review of nanosuspension formulation and process analysis in wet media milling using microhydrodynamic model and emerging characterization methods. International Journal of Pharmaceutics, 623, 121862.

[11] Raval, J. A., Patel, J. K., & Patel, M. M. (2006). Nanosuspensions as particulate drug delivery systems. Pharma Review, 4, 5.

[12] Bose, S., Sharma, P., Mishra, V., Patial, S., Saraogi, G. K., Tambuwala, M. M., & Dua, K. (2023). Comparative in vitro evaluation of glimepiride containing nanosuspension drug delivery system developed by different techniques. Journal of Molecular Structure, 129927.

[13] Bhatt, D. C. (2023). Development, optimization and characterization of glimepiride nanosuspension with improved solubility and dissolution. International Journal of Drug Delivery Technology, 13(4), 13–27.

[14] Rampurawala, M., Shah, C., & Upadhyay, U. (2024). Nano-suspension: A novel and emerging approach in pharmaceutical drug delivery. International Journal of Pharmaceutical Sciences, 2(9), 133–146.

[15] Nayak, B. S., Mohanty, B., Roy, H. K., & Patnaik, A. (2019). Nanosuspension: Bioavailability enhancement novel approaches. 8(2), 540–554.

[16] Kalvakuntla, S., Deshpande, M., Attari, Z., & Kunnatu, K. (2016). Preparation and characterization of nanosuspension of aprepitant by H96 process. Advanced Pharmaceutical Bulletin, 6(1), 83–90.

[17] Patel, V. R., & Agrawal, Y. K. (2011). Nanosuspension: An approach to enhance solubility of drugs. Journal of Advanced Pharmaceutical Technology & Research, 2(2), 137–147.

[18] Tandekar, S., & Mote, U. (2024). Nanosuspension in drug delivery. International Journal of Pharmaceutical Sciences, 2(11), 1768–1776.

[19] Fathi-Karkan, S., Ramsheh, N. A., Arkaban, H., Narooie-Noori, F., Sargazi, S., Mirinejad, S., ... & Rahman, M. M. (2024). Nanosuspensions in ophthalmology: Overcoming challenges and enhancing drug delivery for eye diseases. International Journal of Pharmaceutics, 124226.

[20] Liversidge, G. G., & Cundy, K. C. (1995). Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. International Journal of Pharmaceutics, 125, 91–97.

[21] Ding, X., Guo, L., Du, Q., Wang, T., Zeng, Z., Wang, Y., & Cui, B. (2024). Preparation and comprehensive evaluation of the efficacy and safety of chlorantraniliprole nanosuspension. Toxics, 12(1), 786.

[22] Detroja, C., Chavhan, S., & Sawant, K. (2011). Enhanced antihypertensive activity of candesartan cilexetil nanosuspension: Formulation, characterization and pharmacodynamic study. Scientia Pharmaceutica, 79, 635–651.

[23] Singh, S. K., Srinivasan, K. K., Gowthamarajan, K., Singare, D. S., Prakash, D., & Gaikwad, N. B. (2011). Investigation of preparation parameters of nanosuspension by top-down media milling to improve the dissolution of poorly water-soluble glyburide. European Journal of Pharmaceutics and Biopharmaceutics, 78, 441–446.

[24] Hu, X., Chen, X., Zhang, L., Lin, X., Zhang, Y., & Tang, X. (2014). A combined bottom-up/top-down approach to prepare a sterile injectable nanosuspension. International Journal of Pharmaceutics, 472(1–2), 130–139.

[25] Rahim, H., Sadiq, A., Khan, S., Amin, F., Ullah, R., Shahat, A. A., & Mahmood, H. M. (2019). Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition. International Journal of Nanomedicine, 14, 6287–6296.

[26] Jadhav, P., & Yadav, A. (2019). Formulation, optimization, and in vitro evaluation of polymeric nanosuspension of flurbiprofen. Asian Journal of Pharmaceutical and Clinical Research, 12(11), 183–191.

[27] Phan, A. N. Q., Bach, L. G., Nguyen, T. D., & Le, N. T. H. (2019). Efficient method for preparation of rutin nanosuspension using chitosan and sodium tripolyphosphate crosslinker. Journal of Nanoscience and Nanotechnology, 19(2), 974–978.

[28] Chaudhary, S. K., Mahmoudi, N., Rao, P. B., & Chakraborty, J. (2016). Aceclofenac nanosuspension: Formulation and evaluation. Unique Journal of Pharmaceutical and Biological Sciences, 4, 11–19.

[29] Kathpalia, H., Juvekar, S., & Shidhaye, S. (2019). Design and in vitro evaluation of atovaquone nanosuspension prepared by pH-based and anti-solvent-based precipitation method. Colloid and Interface Science Communications, 29, 26–32.

[30] Alshweiat, A., Katona, G., Csóka, I., & Ambrus, R. (2018). Design and characterization of loratadine nanosuspension prepared by ultrasonic-assisted precipitation. European Journal of Pharmaceutical Sciences, 122, 94–104.

Downloads

Published

2026-06-30

How to Cite

Samanta, R., Deo, P., Sutar, R. K., Behera, H., Goswami, T. D., & Panda, A. (2026). Formulation and Characterization of Glimepiride Nanosuspension to Improve the Solubility and Release of Drug. Journal for Research in Applied Sciences and Biotechnology, 5(3), 112–118. https://doi.org/10.55544/jrasb.5.3.16

Issue

Vol. 5 No. 3 (2026): June Issue

Section

Articles

License

Copyright (c) 2026 Radheshyam Samanta, Pravati Deo, Ranjit Kumar Sutar, Hrushikesh Behera, Tamal Deb Goswami, Ayush Panda

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Similar Articles

You may also start an advanced similarity search for this article.